THERAPY DOSSIER · th-d230a3b2391a

Apelin-13

Hormone

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00901719 ↗NAcompleted

Interaction of Apelin and Systemic Angiotensin II on Resistance Vessels and Haemodynamics in Man (Apelin infusion)

Heart Failure · Vasodilatation

Enrolment: 12 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28736029 ↗2017Reported benefit

Protective Role of Apelin Against Cyclosporine-Induced Renal Tubular Injury in Rats.

RatChemical/toxinMaleSubcutaneous injectionApelin-13 15 micrograms/kg/day; ciclosporin A 15 mg/kg/dayCo-administered with ciclosporin A over the 7-day exposure period

Model: Ciclosporin A (15 mg/kg/day) given subcutaneously for 7 days to induce renal tubular injury without glomerular filtration rate reduction

Ciclosporin A produced increased urinary creatinine excretion, polyuria, renal glycosuria and raised urinary NGAL without reducing glomerular filtration rate. Apelin-13 attenuated the tubular injury and lowered tubulo-interstitial injury scores, with the authors attributing the effect to nitric oxi…

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…